AGE-STANDARDIZED MORTALITY RATES IN THE CARIBBEAN: ONE SOURCE, THREE DIFFERENT INTERPRETATIONS





The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer

Immune checkpoint blockade (ICB) has become a standard treatment for non-small cell lung cancer (NSCLC).However, most patients with NSCLC do not benefit from these treatments.Abnormal vasculature is a hallmark of solid tumors and is involved in tumor immune escape.These abnormalities stem from the increase in the expression of pro-angiogenic factor

read more